Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Keros Therapeutics ( (KROS) ) has issued an announcement.
On January 30, 2025, Keros Therapeutics announced that its CEO, Jasbir Seehra, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025. This event allows Keros to highlight its strategic initiatives and potentially boost its industry positioning, offering insights to stakeholders on its ongoing developments and market focus.
More about Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. Keros is a leader in understanding the TGF-ß family, which regulates the growth, repair, and maintenance of various tissues. Their product candidates include cibotercept for pulmonary arterial hypertension and cardiovascular disorders, KER-065 for neuromuscular diseases, and elritercept for treating cytopenias in myelodysplastic syndrome and myelofibrosis.
YTD Price Performance: -28.58%
Average Trading Volume: 1,471,835
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $458.1M
See more data about KROS stock on TipRanks’ Stock Analysis page.
